Literature DB >> 20597139

HMGA2 gene expression analysis performed on cytologic smears to distinguish benign from malignant thyroid nodules.

Paul J Lappinga1, N Sertac Kip, Long Jin, Ricardo V Lloyd, Michael R Henry, Jun Zhang, Aziza Nassar.   

Abstract

BACKGROUND: Up to 80% of thyroid nodules with an indeterminate diagnosis on fine-needle aspiration (FNA) (eg, "suspicious for follicular neoplasm") prove to be benign at the time of surgical resection. Ancillary tests in current use are limited in their ability to improve the preoperative detection of malignant follicular thyroid nodules. Studies using paraffin-embedded tissue have indicated that high mobility group AT-hook 2 (HMGA2) overexpression is present in a high percentage of malignant thyroid neoplasms but not in benign thyroid neoplasms. In the current study, the ability of HMGA2 overexpression analysis to preoperatively distinguish benign from malignant thyroid nodules by reverse transcriptase-polymerase chain reaction (RT-PCR) on suspicious cytologic smears was evaluated.
METHODS: Patients who underwent thyroid FNA and subsequent thyroid resection from 2001 through 2007 were identified. A subset of these patients who had a cytologic diagnosis of "suspicious" underwent HMGA2 expression analysis. HMGA2 expression was detected on cells scraped from cytologic smears with 1-step, real-time quantitative RT-PCR.
RESULTS: Of the 125 cases identified, RNA extraction and HMGA2 analysis were successful in 115 cases. With an HMGA2 overexpression change of 5.9-fold or greater compared with a thyroid tumor cell line as a positive cutoff, the test was found to have the following overall performance for detecting malignant nodules: sensitivity of 71%, specificity of 97%, positive predictive value of 94%, and negative predictive value of 84%. HMGA2 overexpression was found to have low sensitivity for detecting Hurthle cell carcinoma (33%).
CONCLUSIONS: HMGA2 mRNA expression analysis can be performed on cytologic smears and demonstrates a high specificity and positive predictive value and relatively high sensitivity and negative predictive value for detecting malignancy in "suspicious" thyroid aspirate specimens.
© 2010 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20597139     DOI: 10.1002/cncy.20095

Source DB:  PubMed          Journal:  Cancer Cytopathol        ISSN: 1934-662X            Impact factor:   5.284


  12 in total

Review 1.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

Review 2.  Papillary thyroid carcinoma variants.

Authors:  Ricardo V Lloyd; Darya Buehler; Elham Khanafshar
Journal:  Head Neck Pathol       Date:  2011-01-08

3.  MicroRNAs let7 expression in thyroid cancer: correlation with their deputed targets HMGA2 and SLC5A5.

Authors:  Alexander I Damanakis; Sabine Eckhardt; Annette Wunderlich; Silvia Roth; Thaddeus T Wissniowski; Detlef K Bartsch; Pietro Di Fazio
Journal:  J Cancer Res Clin Oncol       Date:  2016-03-09       Impact factor: 4.553

Review 4.  Molecular genetics and diagnosis of thyroid cancer.

Authors:  Yuri E Nikiforov; Marina N Nikiforova
Journal:  Nat Rev Endocrinol       Date:  2011-08-30       Impact factor: 43.330

5.  A panel of four genes accurately differentiates benign from malignant thyroid nodules.

Authors:  Qing-Xuan Wang; En-Dong Chen; Ye-Feng Cai; Quan Li; Yi-Xiang Jin; Wen-Xu Jin; Ying-Hao Wang; Zhou-Ci Zheng; Lu Xue; Ou-Chen Wang; Xiao-Hua Zhang
Journal:  J Exp Clin Cancer Res       Date:  2016-10-28

6.  Thyroid follicular adenomas and carcinomas: molecular profiling provides evidence for a continuous evolution.

Authors:  Geneviève Dom; Sandra Frank; Sebastien Floor; Pashalina Kehagias; Frederick Libert; Catherine Hoang; Guy Andry; Alex Spinette; Ligia Craciun; Nicolas de Saint Aubin; Christophe Tresallet; Frederique Tissier; Frederique Savagner; Samira Majjaj; Ilse Gutierrez-Roelens; Etienne Marbaix; Jacques E Dumont; Carine Maenhaut
Journal:  Oncotarget       Date:  2017-12-08

7.  Long noncoding RNA ZFAS1 promotes progression of papillary thyroid carcinoma by sponging miR-590-3p and upregulating HMGA2 expression.

Authors:  Houchao Tong; Xi Zhuang; Jingsheng Cai; Yu Ding; Yan Si; Hao Zhang; Meiping Shen
Journal:  Onco Targets Ther       Date:  2019-09-13       Impact factor: 4.147

Review 8.  Mechanisms of therapeutic resistance in cancer (stem) cells with emphasis on thyroid cancer cells.

Authors:  Sabine Hombach-Klonisch; Suchitra Natarajan; Thatchawan Thanasupawat; Manoj Medapati; Alok Pathak; Saeid Ghavami; Thomas Klonisch
Journal:  Front Endocrinol (Lausanne)       Date:  2014-03-25       Impact factor: 5.555

9.  Correlated expression of HMGA2 and PLAG1 in thyroid tumors, uterine leiomyomas and experimental models.

Authors:  Markus Klemke; Marietta Henrike Müller; Werner Wosniok; Dominique Nadine Markowski; Rolf Nimzyk; Burkhard Maria Helmke; Jörn Bullerdiek
Journal:  PLoS One       Date:  2014-02-07       Impact factor: 3.240

Review 10.  Current Standards and Recent Advances in Biomarkers of Major Endocrine Tumors.

Authors:  Yanhong Luo; Hua Zhu; Tao Tan; Jianfeng He
Journal:  Front Pharmacol       Date:  2018-09-10       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.